Drug Trial Radar · NCT07197554
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
171
Planned (sponsor's estimate)
Start
Dec 1, 2025
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- SEED Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Conditions
- Advanced Solid Tumors
- Ewing Sarcoma
- Hepatocellular Carcinoma (HCC)
- Biliary Tract Cancer (BTC)
Interventions
ST-01156Drug
ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Dose EscalationTime frame: First 28 days of treatment
- Part 1: Dose EscalationTime frame: Duration of treatment period
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
The City of Hope National Medical Center
Duarte, California · Recruiting
Hoag Memorial Hospital
Newport Beach, California · Recruiting
Mass General Brigham Cancer Institute
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.